In other tumor types, immune checkpoint therapies are approved as part of combination therapies, regardless of the PD-L1 expression, as exemplified by the current National Comprehensive Cancer Network guidelines, including the use of pembrolizumab as part of combination therapies in certain patients with non-small cell lung carcinoma [7,10]. This evidence concerns the gene CD274 and neoplasm.